ArchiveSeptember 2018

DMF inhibiting B cells numbers

  Times are a changing folks.  Not a year ago the same type of phenotpying data was reported in the blood of people treated with DMF.  The focus has now changed, guess where. B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate. Høglund RA, Polak J, Vartdal F, Holmøy T, Lossius A. Mult Scler Relat Disord. 2018 Sep 6;26:90-95...

Treating Fatigue with Stem Cells

  Fatigue is the symptom which has been high on the agenda for research into its cause and cure. It seems this is a sickness behaviour as a consequence of inflammation within the CNS. It is probable that it is caused, at least in part, by inflammatory cytokines. Therefore, if you get rid of inflammation, fatigue may be reduced. We first saw this with natalizumab and so it is the cases...

ECTRIMS 2018… here we go again!

In little over 2 weeks’ time, the MS professional community will travel to Berlin for the 34th ECTRIMS meeting. It’s the largest European conference focusing on MS research and treatment, and is attended by MS healthcare professionals, companies, researchers and charities.   Similar to previous years, the Barts-MS team are keen to get some of this new research out to you as quickly as...

Guest Post: The Real, Real Deal with Exercising and MS

Oh no. No, no, no, you’re thinking. Not another Barts MS Blog lecture on the importance of exercising when you have multiple sclerosis. Especially a guest blog from that Dave guy who runs ActiveMSers.org and who thinks he is funny and has no professional medical or physical fitness credentials—just a dude who runs a blog, ruffles feathers like Gavin, and works out. I get it. I mean, I could point...

And the risk-sharing scheme results…

J Neurol Neurosurg Psychiatry. 2018 Sep 21. pii: jnnp-2018-318360. doi: 10.1136/jnnp-2018-318360. [Epub ahead of print] Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme. Palace J, Duddy M, Lawton M, Bregenzer T, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H...

Old but good news: children and adolescents get their first licensed DMT in Europe

I personally want to thank all those involved in getting fingolimod licensed as the first disease-modifying therapy for children and adolescents with MS. Getting this trial done was a ‘mission impossible’. Novartis, the steering committee, investigators and all study participants must be congratulated on getting past the finish line. History will judge this as an important...

A quick summary of Prof G’s Twitter activity (17-23 Sept 2018)

If rapamycin works in MS does it mean the T-reg hypothesis is back on the table? I suspect not. #ResearchSpeak pic.twitter.com/tb6ODTluWn — Gavin Giovannoni (@GavinGiovannoni) September 18, 2018 More hype over substance! #ClinicSpeak Stem cell therapy for neurological disorders: A focus on aging. pic.twitter.com/zIQnUi5v3D — Gavin Giovannoni (@GavinGiovannoni) September 18, 2018 An interesting...

Papers during the week

  Here are some papers you may or may not find interesting Whilst NICE no longer supports the use of CRAB drugs, this study does say that on first signs of MS, these agents work although it takes a few months to see this. So we wait to see what are the consequences of early intervention with a high activity agent. Problem is NICE has tied the hands of the neuro on this one. Maybe time to re...

Is EAE a valid tool if studying MS

Mouse EAEers currently use myelin oligodendrocyte glycoprotein to induce disease, with which to study MS. However, do people with MS respond to this protein Papp V, Langkilde AR, Blinkenberg M, Schreiber K, Jensen PEH, Sellebjerg F. Clinical utility of anti-MOG antibody testing in a Danish cohort. Mult Scler Relat Disord. 2018 Sep 11;26:61-67. doi: 10.1016/j.msard.2018.09.010. [Epub...

Translate

Categories

Recent Posts

Recent Comments

Archives